Federal election: PBS script savings regardless of who’s elected
Both sides of the political divide are promising to slash the maximum price Australians pay for a PBS script, if ...
Both sides of the political divide are promising to slash the maximum price Australians pay for a PBS script, if ...
The Federal Government has laid out a $132 billion health agenda for the coming year – if it regains power ...
Almost 13,000 Australians could save thousands annually with the Pharmaceutical Benefits Scheme (PBS) listing of Beovu (brolucizumab) for neovascular age-related ...
An independent expert panel has recommended Novartis' treatment Beovu be subsidised through the Pharmaceutical Benefits Scheme (PBS) for neovascular age-related ...
The Australian government spent more than $610 million on anti-VEGF treatments during the past year, with aflibercept (Eylea) leapfrogging a ...
New regulations come into force from 1 February requiring doctors to prescribe PBS drugs by their active ingredient instead of ...
Novartis has announced positive findings from its the Phase 3 trial assessing the efficacy and safety of Beovu (brolucizumab) to ...
Dry eye remains a very common presentation to primary eyecare practitioners in Australia. Many experienced practitioners feel that the incidence ...
Prednefrin Forte eye drops can now be prescribed to Aboriginal and Torres Strait Islander patients under the Pharmaceutical Benefits Scheme ...
A new formulation of the Jetrea intravitreal injection has been listed on Pharmaceutical Benefits Scheme (PBS), replacing the current powder ...
Insight has been the leading industry publication in Australia for more than 40 years. This longevity is largely due to our ability to consistently deliver accurate and independent news relevant to all ophthalmic professionals and their supporting industry.
© 2025 All Rights Reserved. All content published on this site is the property of Prime Creative Media. Unauthorised reproduction is prohibited
© 2025 All Rights Reserved. All content published on this site is the property of Prime Creative Media. Unauthorised reproduction is prohibited